Celularity Inc - Ordinary Shares - Class A

NASDAQ:CELU  
4.31
+0.34 (+8.56%)
Products

Celularity Announces FDA Clearance Of Investigational New Drug Application For Natural Killer Cell Therapy CYNK-101

Published: 11/29/2021 13:08 GMT
Celularity Inc - Ordinary Shares - Class A (CELU) - Celularity Announces FDA Clearance of Investigational New Drug Application (ind) for Natural Killer Cell Therapy Cynk-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer.
Celularity Announces FDA Clearance of Investigational New Drug Application (ind) for Natural Killer Cell Therapy Cynk-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer.